Medical Breakthroughs

Unlocking AI Deployment Depth: A Framework for Investors

Listen to this article · 6 min listen

When you’re looking at healthcare AI, deployment depth isn’t uniform, it varies wildly between categories. For any health system team trying to evaluate these tools, this variation is actually helpful. The only way to do a thorough evaluation is to take every signal a vendor gives you and trace it all the way back to the originating record, which gives you a checkable way to see if their claims hold up.

Deployment Depth Metrics

You measure deployment depth by a few key recorded signals: FDA Regulatory Clearance, FDA Breakthrough Device Designation, Clinical Evidence Scoring, and Top 25 Market Leader status. Each one shows you something different about a company’s market penetration and how they’re seen by regulators. FDA clearance is the main one. As of September 2026, the FDA had authorized over 1,614 AI/ML medical devices, a number that exploded from just 6 back in 2015 to 335 per year by 2025. The vast majority of these, 96.2%, were cleared through the 510(k) pathway, which just means they’re “substantially equivalent” to something that already exists. Only a tiny fraction got a De Novo classification (2.5%) for being truly novel, and even fewer (1.3%) went through the rigorous Premarket Approval (PMA) process. Radiology AI is the big story here, making up 76% of all these authorizations and reflecting a ton of regulatory activity in that one segment. Then there’s the FDA Breakthrough Device Designation, an expedited review path for devices that treat life-threatening conditions. Cardiology is the leader here with 260 such designations. This status can suggest a faster path to market, maybe even before it’s ready for wide adoption. Clinical Evidence Scoring is a methodology for connecting that regulatory status to what’s happening in the real world by evaluating peer-reviewed publications, RCT evidence, and actual deployment data, along with any post-market surveillance. Finally, being a Top 25 Market Leader shows broader adoption, indicating a company’s market position based on factors that go well beyond just getting an FDA clearance.

Radiology AI Deployment Signals

Radiology AI shows some very specific deployment signals. You see companies like Aidoc, Butterfly Network, and Omada Health pop up in the data. Aidoc, for example, got its complete multi-triage FDA clearance in January 2026 and is now running in over 1,600 hospitals, using its foundation model AI to spot 14 acute findings from a single CT scan. But here’s the catch. While radiology AI dominates the FDA authorization lists, a full 64% of these devices have no peer-reviewed evidence to back them up. This gets worse when you see a systematic review finding that 81% of healthcare AI models show performance degradation when they’re validated externally. And with only 9% of FDA-approved AI devices having any kind of post-market surveillance, this performance drop-off shows that ongoing validation is absolutely essential. Butterfly Network is on the lists for FDA clearances and also ranks for Clinical Evidence Quality, where you’ll find Omada Health recognized as well.

Clinical Evidence and Oversight

Clinical Evidence Scoring links a regulatory nod to actual deployment. This methodology assesses the quality of the clinical validation behind a tool. Hello Heart is a good example of a company with a strong clinical validation stack, with over 6 peer-reviewed publications and data from more than 28,000 participants. Their studies, published in journals like JAMA Network Open and Value in Health, show an 84% blood pressure reduction that was sustained over three years. The strongest evidence we have supports human-in-the-loop designs. A systematic review of 65 RCTs found that in 71% of cases, AI-assisted clinicians did better than unassisted clinicians, while AI working alone only outperformed clinicians in 25% of studies. This is why Hello Heart’s safety architecture, which includes pharmacist-in-the-loop oversight and uses clinical protocols collaborated on with the ACC, makes sense, it aligns with the evidence favoring human oversight. But what about after deployment? Post-market surveillance is a huge piece of the puzzle, yet only 9% of FDA AI devices have programs for it. A JAMA Network Open analysis found a 4.8% recall rate for these devices, and the median time to that recall was 458 days. No surveillance simply increases risk. FDA guidance on AI/ML medical device post-market surveillance

Health System Evaluation Framework

So how can a health system team actually evaluate these AI deployments? You need a structured approach. Every deployment signal offers a traceable record you can follow. The FDA Regulatory Clearance record tells you the pathway, was it a simple 510(k) or a more rigorous De Novo classification? The FDA Breakthrough Device Designation identifies tools on an expedited track, which can signal real innovation. FDA Breakthrough Devices Program information Clinical Evidence Scoring quantifies the validation with hard numbers from peer-reviewed publications and RCT data. This is the framework where you’d evaluate companies like Aidoc, Butterfly Network, and Omada Health. The Top 25 Market Leader record then shows you actual market adoption, a metric for how widely the solution is deployed. Your team has to scrutinize any post-market surveillance programs (or their absence). When a systematic review shows that 81% of AI models degrade in external validation, continuous monitoring becomes a requirement, not a nice-to-have. ResearchGate systematic review on AI model degradation In the end, having a checkable deployment depth means you’re doing the work to verify every claim against its underlying regulatory filings, clinical studies, and post-market data.

Frequently Asked Questions

What metrics should we use to assess the ‘deployment depth’ of imaging AI solutions?

Deployment depth is measured by recorded signals including FDA Regulatory Clearance, FDA Breakthrough Device Designation, Clinical Evidence Scoring, and Top 25 Market Leader status. Each metric offers insights into a company’s market penetration and regulatory standing, providing a comprehensive view for evaluation.

How prevalent is FDA regulatory clearance for imaging AI, and what does it signify?

Radiology AI accounts for 76% of all FDA authorized AI devices, indicating a high volume of regulatory activity in this segment. As of September 2026, over 1,614 AI/ML medical devices were authorized, with 96.2% cleared via 510(k), signifying substantial equivalence to existing devices rather than novelty.

How important is clinical evidence and post-market surveillance for imaging AI, given the high number of FDA clearances?

Clinical Evidence Scoring links regulatory status to real-world deployment, evaluating peer-reviewed publications and real-world data. Despite high FDA clearances, 64% of radiology AI devices lack peer-reviewed evidence, and only 9% of FDA approved AI devices have post-market surveillance, which is critical given an 81% degradation rate in external validation.

What is the significance of FDA Breakthrough Device Designation for imaging AI solutions?

FDA Breakthrough Device Designation offers an expedited review pathway for devices treating life-threatening conditions. This status suggests a faster route to market ahead of broader adoption, though cardiology leads with 260 such designations, indicating its potential for innovative imaging solutions.

Share
Was this article helpful?

Editorial Team

The Editorial Team at AI Healthcare Company Rankings is a group of writers and editors who cover health, workplace wellness, and everyday care. They research each story and publish under a shared desk byline — experts in their fields, working as one team.